Immune response in neuronal tissue is a “double-edged sword” representing a fine balance between protective antipathogen responses and detrimental neurocytotoxic effects. Neuronal inflammation is, therefore, tightly regulated at multiple levels, including neuron-to-microglia, microglia-to-astrocyte, and astrocyte-to-neuron interactions to ensure beneficial effects of the response. Microglia are the main innate immune cells safeguarding the neuronal tissue. Like other innate immune cells, microglia express pattern-recognition receptors (PRRs), including toll-like receptors (TLRs)
1,2 and NOD-like receptors (NLRs),
3 which can bind various pathogen-associated molecular patterns (PAMPs), leading to microglial activation. In addition to PRRs, various other molecules are also involved in microglial activation. Fractalkine (CX3CL1) is constitutively produced by neurons in the CNS,
4,5 including the neural retina,
6–8 whereas its receptor CX3CR1 is exclusively expressed by microglial cells.
5,8,9 CX3CL1–CX3CR1 signaling is one of the main pathways involved in neuron–microglia interactions and plays a crucial role in regulating microglial activation.
5,9,10 Under physiological conditions, the CX3CL1–CX3CR1 pathway is known to suppress microglial activation.
9 However, under pathologic conditions, the role of the CX3CL1–CX3CR1 pathway in neuronal inflammation is controversial.
Early work by Cardona et al.
9 has shown that CX3CR1 is important in controlling microglial neurotoxicity. In the absence of CX3CR1, microglial responses to stimuli (lipopolysaccharide and damaged neuronal tissues) are dysregulated, leading to neurotoxicity.
9 The neuroprotective role of the CX3CL1–CX3CR1 pathway has also been observed in other neurodegenerative and neuroinflammatory diseases.
11,12 In addition, in vitro studies have shown that both soluble and membrane-bound fractalkines attenuate lipopolysaccharide–induced microglial activation, and fractalkine suppresses microglial activation through the PI3K pathway.
13 In contrast to these observations, in the models of CNS ischemia/reperfusion, lesion development was protected in both CX3CR1-deficient mice
14 and CX3CL1-deficient mice,
15 and the protection was related to reduced IL-1β and TNF-α expression and decreased leukocyte infiltration in those mice.
14 Furthermore, CX3CL1–CX3CR1 deletion promotes recovery after spinal cord injury by limiting the recruitment and activation of Ly6C
lo/iNOS
+ macrophages.
16
In the retina, CX3CR1 is not required for the distribution and recruitment of microglia under normal physiological conditions.
8 In a radiation-induced retinal parainflammation model, although Fractalkine (CX3CL1) expression is temporarily upregulated, the CX3CR1 pathway is not involved in the recruitment of bone marrow–derived myeloid cells.
17 Under inflammatory conditions (e.g., uveitis), CX3CL1 expression is increased.
6 However, CX3CR1 deficiency does not appear to affect the severity of retinal inflammation in a model of experimental autoimmune uveoretinitis,
18 although a mild increase in disease severity was observed in another study.
19 During aging, CX3CR1 deficiency results in increased microglial activation and subretinal migration and retinal degeneration.
20 The role of the CX3CL1–CX3CR1 pathway in retinal immunity remains to be fully elucidated.
In this study, we investigated the role of CX3CR1 in oxidative damage–mediated retinal degeneration in the paraquat injection model previously reported by Cingolani and colleagues.
21 We show that paraquat-mediated retinal degeneration is accompanied by an acute retinal inflammation characterized by increased inflammatory gene expression (e.g.,
TNF-α and
iNOS), microglial activation, and the recruitment of circulating neutrophils and monocytes. In the absence of CX3CR1, the inflammatory response was exaggerated and was related to severe retinal degeneration.